AA
PCRX icon

ALPS Advisors’s Pacira BioSciences PCRX Stock Holding History

ALPS Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-72,484
Closed -$3.56M – 923
2018
Q3 		$3.56M Buy
72,484
+13,370
+23% +$578K 0.02% 188
2018
Q2 		$1.9M Buy
59,114
+4,701
+9% +$162K 0.01% 234
2018
Q1 		$1.7M Buy
54,413
+9,457
+21% +$337K 0.01% 227
2017
Q4 		$2.05M Buy
44,956
+5,225
+13% +$207K 0.01% 195
2017
Q3 		$1.49M Buy
39,731
+3,546
+10% +$143K 0.01% 207
2017
Q2 		$1.73M Buy
36,185
+4,008
+12% +$186K 0.01% 191
2017
Q1 		$1.47M Sell
32,177
-3,766
-10% -$163K 0.01% 189
2016
Q4 		$1.16M Sell
35,943
-11,581
-24% -$386K 0.01% 208
2016
Q3 		$1.63M Sell
47,524
-4,688
-9% -$184K 0.01% 198
2016
Q2 		$1.76M Buy
52,212
+10,542
+25% +$518K 0.02% 178
2016
Q1 		$2.21M Sell
41,670
-6,752
-14% -$395K 0.02% 148
2015
Q4 		$3.72M Sell
48,422
-8,938
-16% -$506K 0.04% 135
2015
Q3 		$2.36M Buy
57,360
+21,190
+59% +$1.3M 0.02% 156
2015
Q2 		$2.56M Buy
36,170
+18,135
+101% +$1.43M 0.02% 150
2015
Q1 		$1.6M Buy
+18,035
New +$1.83M 0.01% 161

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ALPS Advisors's PCRX Position: Q4 2018 in Review

ALPS Advisors sold out of Pacira BioSciences (PCRX) in Q4 2018, closing a stake of 72,484 shares — an estimated $3.56M sold.

ALPS Advisors first reported a position in PCRX in Q1 2015 and held it in 15 quarters. The position peaked at $3.72M in Q4 2015. 208 funds tracked by Wall St. Rank hold PCRX as of Q4 2018.

  • ALPS Advisors reported no remaining Pacira BioSciences position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 72,484 Pacira BioSciences shares in Q4 2018, an estimated $3.56M.
  • ALPS Advisors first reported a position in Pacira BioSciences in Q1 2015 and held it in 15 quarters.
  • ALPS Advisors's Pacira BioSciences position peaked at $3.72M in Q4 2015.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.